Hepion Pharmaceuticals, Inc. Form SCHEDULE 13D — Oct 26, 2026
Gravitas Collective Corp. filed a Schedule 13D disclosing beneficial ownership of 25,000,000 shares of Hepion Pharmaceuticals common stock, representing 19.9% of the class, with an event date of October 6, 2026. The shares were acquired in exchange for the membership interests of Gravitas Life Sciences, Inc., a wholly owned subsidiary of the reporting person, meaning the stake was obtained through a share-for-asset swap rather than an open-market purchase.
Key figures
- Shares Outstanding
- 0
- Percent of class
- 19.9%
- Shares beneficially owned
- 25000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.